Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1.15p 1.10p 1.20p 1.15p 1.15p 1.15p 26,873 07:50:30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.3 -0.4 -0.0 - 65.57

Physiomics PLC Issue of Options

22/12/2016 7:00am

UK Regulatory (RNS & others)


Physiomics (LSE:PYC)
Historical Stock Chart

1 Year : From Aug 2016 to Aug 2017

Click Here for more Physiomics Charts.

TIDMPYC

RNS Number : 5159S

Physiomics PLC

22 December 2016

Physiomics plc

The Magdalen Centre

The Oxford Science Park

Robert Robinson Avenue

Oxford

OX4 4GA

UK

Tel 01865 784980

Fax 08701 671931

22(nd) December 2016

Physiomics plc

("Physiomics") or ("the Company")

Issue of Options

The Company confirms that it has agreed to issue share options to its directors, as follows:

1. 879,521 share options over ordinary shares in the Company ("Share Options") have been granted to Christophe Chassagnole under the Enterprise Management Initiative Scheme ("EMI"). The options are exercisable at a price of 2.5p each (being the price of the placing carried out by the company on the 21(st) September this year adjusted for the share consolidation carried out on the 19(th) December).

2. 1,938,564 share options over ordinary shares in the Company ("Share Options") have been granted to Jim Millen under the Enterprise Management Initiative Scheme ("EMI"). The options are exercisable at a price of 2.5p each (being the price of the placing carried out by the company on the 21(st) September this year adjusted for the share consolidation carried out on the 19(th) December).

The options vest based on a combination of performance and time based criteria and can be exercised within 10 years of the date of grant.

Following this issue, Jim Millen will hold options over 1,938,564 ordinary shares of the Company and Christophe Chassagnole will hold options over 2,258,883 ordinary shares in the Company in accordance with the table below.

In addition, Christophe Chassagnole owns 151,897 ordinary shares (equivalent to 0.27% of the currently issued share capital).

 
 Option holder    # Options   Exercise     Expiry 
                               price(p)      date 
---------------  ----------  ----------  ---------- 
 
 C Chassagnole     74,994      38.300     06-Sep-17 
                   56,245      15.000     18-Dec-18 
                   118,565     40.000     29-Feb-20 
                   32,331      34.000     08-Nov-21 
                   129,381     13.200     11-Feb-23 
                   322,615      6.167     23-Mar-25 
                   645,231      3.500     20-Dec-25 
                   879,521      2.500     21-Dec-26 
 
 J Millen         1,938,564     2.500     21-Dec-26 
 

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

WH Ireland Limited (nomad)

Katy Mitchell

+44 (0) 161 832 2174

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million(1) .

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell(R) technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell(R) is a registered trademark of Physiomics plc

(1) Tufts Centre Impact Report 2002

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHTBBITMBATBAF

(END) Dow Jones Newswires

December 22, 2016 02:00 ET (07:00 GMT)

1 Year Physiomics Chart

1 Year Physiomics Chart

1 Month Physiomics Chart

1 Month Physiomics Chart
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V:gb D:20170817 21:37:30